Repeated Full-Face Aesthetic Combination Treatment With AbobotulinumtoxinA, Hyaluronic Acid Filler, and Skin-Boosting Hyaluronic Acid After Monotherapy With AbobotulinumtoxinA or Hyaluronic Acid Filler.
Acetylcholine Release Inhibitors
/ administration & dosage
Adult
Botulinum Toxins, Type A
/ administration & dosage
Combined Modality Therapy
/ methods
Cosmetic Techniques
Dermal Fillers
/ administration & dosage
Esthetics
Face
Female
Humans
Hyaluronic Acid
/ administration & dosage
Male
Middle Aged
Patient Satisfaction
Rejuvenation
Retreatment
/ methods
Skin Aging
Treatment Outcome
Journal
Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
ISSN: 1524-4725
Titre abrégé: Dermatol Surg
Pays: United States
ID NLM: 9504371
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
pubmed:
9
10
2019
medline:
31
10
2020
entrez:
9
10
2019
Statut:
ppublish
Résumé
Full-face aesthetic treatment involving several treatment modalities may improve facial aesthetic outcome. To evaluate clinical outcomes and patient perceptions of monotherapy with either abobotulinumtoxinA (ABO) or hyaluronic acid (HA) filler followed by full-face combination treatments of ABO, HA filler, and skin-boosting HA (RSB). Subjects aged 35 to 50 years were randomized to monotherapy with 50 s.U ABO in the glabella or ≤1 mL HA filler in the nasolabial folds (NLFs)/cheeks. At Month 6 and Month 12, all subjects received combination treatment with ≤50 s.U ABO in the glabella, ≤2 mL HA filler in the NLFs/cheeks (and other facial areas as applicable), and ≤1 mL RSB (additional RSB treatment at Month 7). Assessments included global facial aesthetic appearance and improvement, first impression, perceived age, wrinkle severity, satisfaction questionnaires, and adverse events. Repeated full-face combination treatment with ABO, HA filler, and RSB was associated with considerably higher levels of aesthetic improvement and subject satisfaction than monotherapy with ABO or HA filler. Improvement rate of glabellar lines was increasing with each treatment. Repeated combination treatment achieved greater change in global facial aesthetic appearance than monotherapy. Aesthetic improvement and subject satisfaction was high and increased with each treatment. All treatments were well tolerated.
Sections du résumé
BACKGROUND
Full-face aesthetic treatment involving several treatment modalities may improve facial aesthetic outcome.
OBJECTIVE
To evaluate clinical outcomes and patient perceptions of monotherapy with either abobotulinumtoxinA (ABO) or hyaluronic acid (HA) filler followed by full-face combination treatments of ABO, HA filler, and skin-boosting HA (RSB).
MATERIALS AND METHODS
Subjects aged 35 to 50 years were randomized to monotherapy with 50 s.U ABO in the glabella or ≤1 mL HA filler in the nasolabial folds (NLFs)/cheeks. At Month 6 and Month 12, all subjects received combination treatment with ≤50 s.U ABO in the glabella, ≤2 mL HA filler in the NLFs/cheeks (and other facial areas as applicable), and ≤1 mL RSB (additional RSB treatment at Month 7). Assessments included global facial aesthetic appearance and improvement, first impression, perceived age, wrinkle severity, satisfaction questionnaires, and adverse events.
RESULTS
Repeated full-face combination treatment with ABO, HA filler, and RSB was associated with considerably higher levels of aesthetic improvement and subject satisfaction than monotherapy with ABO or HA filler. Improvement rate of glabellar lines was increasing with each treatment.
CONCLUSION
Repeated combination treatment achieved greater change in global facial aesthetic appearance than monotherapy. Aesthetic improvement and subject satisfaction was high and increased with each treatment. All treatments were well tolerated.
Identifiants
pubmed: 31592825
doi: 10.1097/DSS.0000000000002165
pmc: PMC7147415
pii: 00042728-202004000-00006
doi:
Substances chimiques
Acetylcholine Release Inhibitors
0
Dermal Fillers
0
Hyaluronic Acid
9004-61-9
Botulinum Toxins, Type A
EC 3.4.24.69
abobotulinumtoxinA
EC 3.4.24.69
Restylane
S270N0TRQY
Types de publication
Clinical Trial, Phase IV
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
475-482Références
J Cosmet Dermatol. 2012 Dec;11(4):267-71
pubmed: 23174049
Dermatol Surg. 2012 Feb;38(2 Spec No.):333-42
pubmed: 22316189
Dermatol Surg. 2011 May;37(5):644-50
pubmed: 21281385
Dermatol Surg. 2017 Jan;43(1):58-65
pubmed: 27673483
J Cosmet Dermatol. 2017 Mar;16(1):132-143
pubmed: 27987257
Dermatol Surg. 2016 May;42 Suppl 2:S168-76
pubmed: 27128245
Dermatol Surg. 2016 Jun;42(6):699-709
pubmed: 27176869
Dermatol Surg. 2015 Dec;41 Suppl 1:S325-32
pubmed: 26618460
J Eur Acad Dermatol Venereol. 2010 Jan;24 Suppl 1:1-14
pubmed: 19930409
J Eur Acad Dermatol Venereol. 2010 Nov;24(11):1278-84
pubmed: 20337830
Dermatol Surg. 2016 May;42 Suppl 2:S89-93
pubmed: 27128250
Arch Dermatol. 2007 Nov;143(11):1447-9
pubmed: 18025375
Dermatol Surg. 2009 Oct;35(10):1478-86
pubmed: 19686365
Dermatol Surg. 2015 Jan;41 Suppl 1:S29-38
pubmed: 25548843
J Am Acad Dermatol. 2004 Aug;51(2):223-33
pubmed: 15280841
Dermatol Surg. 2003 Jun;29(6):588-95
pubmed: 12786700
Dermatol Surg. 2005 Mar;31(3):276-80
pubmed: 15841626
Dermatol Surg. 2007 Jan;33(1 Spec No.):S18-25
pubmed: 17241409
Dermatol Surg. 2012 Jul;38(7 Pt 2):1153-61
pubmed: 22759252
Dermatol Surg. 2012 Feb;38(2 Spec No.):309-19
pubmed: 22316187
Dermatol Surg. 2016 May;42 Suppl 2:S177-91
pubmed: 27128246
Dermatol Surg. 2008 Jun;34 Suppl 1:S2-8; discussion S8
pubmed: 18547177